Ignite Creation Date:
2025-12-25 @ 1:43 AM
Ignite Modification Date:
2025-12-27 @ 12:53 PM
Study NCT ID:
NCT04930094
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-31
First Post:
2021-06-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-10-06
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-07-05
Completion Date Type:
ESTIMATED
First Submit Date:
2021-06-15
First Submit QC Date:
None
Study First Post Date:
2021-06-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-29
Last Update Post Date:
2025-10-31
Last Update Post Date Type:
ESTIMATED